热门资讯> 正文

Natera的Signatera测试将纳入医疗保险范围

2025-06-04 23:01

Natera(NTRA) 0

Natera (NASDAQ:NTRA) said on Wednesday that its genome-based Signatera molecular residual disease test is now covered by Medicare.
The company said that this coverage, under LCD L38779, applies to beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring.
The coverage is similar to previously covered Signatera indications.

More on Natera

Natera: The Clues In Q1 Earnings
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera: Strong Growth Trajectory Despite Stretched Valuation Metrics
SA Asks: What are the best oncology stocks right now?
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。